The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Imatinib Treatment for Idiopathic Pulmonary Fibrosis: Randomized Placebo-controlled Trial Results
Abstract
Rationale: Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease with no known efficacious therapy. Imatinib is a tyrosine kinase inhibitor with potential efficacy to treat fibrotic lung disease. Objectives: To investigate the safety and clinical effects of imatinib in patients with IPF. Methods: We studied 119 patients in an investigator-initiated, multicenter, multinational, double-blind clinical trial to receive imatinib or placebo for 96 weeks. Measurements and Main Results: Over 96 weeks of follow-up, imatinib did not differ significantly from placebo (log rank P = 0.89) for the primary endpoint defined as time to disease progression (10% decline in percent predicted FVC from baseline) or time to death. There was no effect of imatinib therapy on change in FVC at 48, 72, or 96 weeks (P ≥ 0.39 at all time points) or change in diffusing capacity of carbon monoxide at 48, 72, or 96 weeks (P ≥ 0.26 at all time points). Change in resting PaO2 favored imatinib therapy at 48 weeks (P = 0.005) but not at 96 weeks (P = 0.074). During the 96-week trial there were 8 deaths in the imatinib group and 10 deaths in the placebo group (log rank test P = 0.64). Thirty-five (29%) patients discontinued the study without reaching the primary endpoint (imatinib, 32%; placebo, 27%; P = 0.51). Serious adverse events (SAEs) were not more common in the imatinib group (imatinib, 18 SAEs in 17 patients; placebo, 19 SAEs in 18 patients). Conclusions: In a randomized, placebo-controlled trial of patients with mild to moderate IPF followed for 96 weeks, imatinib did not affect survival or lung function. Clinical trial registered with www.clinicaltrials.gov (NCT00131274).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Other immune-modulators and chemotherapeutic agents such as azathioprine, imatinib, and etanercept have not been shown to be effective in IPF patients [51,56–59].”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [59]
Citations
Cites
(2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.165.2.ats01 · Cited by 4,196
Idiopathic Pulmonary Fibrosis: Diagnosis and Treatment: International Consensus Statement
(2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.2.ats3-00 · Cited by 2,628
Incidence and Prevalence of Idiopathic Pulmonary Fibrosis
Raghu, G., Weycker, D., Edelsberg, J., Bradford, W. Z., & Oster, G. (2006) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200602-163oc · Cited by 1,310
Acute Exacerbations of Idiopathic Pulmonary Fibrosis
Collard, H. R., Moore, B. B., Flaherty, K. R., Brown, K. K., Kaner, R. J., King, T. E., Lasky, J. A., Loyd, J. E., Noth, I., Olman, M. A., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200703-463pp · Cited by 1,130
Self-citationReversal of experimental pulmonary hypertension by PDGF inhibition
Schermuly, R. T. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24838 · Cited by 1,058
High-Dose Acetylcysteine in Idiopathic Pulmonary Fibrosis
Demedts, M., Behr, J., Buhl, R., Costabel, U., Dekhuijzen, R., Jansen, H. M., MacNee, W., Thomeer, M., Wallaert, B., Laurent, F., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042976 · Cited by 964
Double-blind, Placebo-controlled Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
Azuma, A., Nukiwa, T., Tsuboi, E., Suga, M., Abe, S., Nakata, K., Taguchi, Y., Nagai, S., Itoh, H., Ohi, M., et al. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200404-571oc · Cited by 954
Imatinib Mesylate — A New Oral Targeted Therapy
Savage, D. G., & Antman, K. H. (2002) · New England Journal of Medicine · doi:10.1056/nejmra013339 · Cited by 844
BUILD-3: A Randomized, Controlled Trial of Bosentan in Idiopathic Pulmonary Fibrosis
King, T. E., Brown, K. K., Raghu, G., du Bois, R. M., Lynch, D. A., Martinez, F., Valeyre, D., Leconte, I., Morganti, A., Roux, S., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201011-1874oc · Cited by 718
A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis
Raghu, G., Brown, K. K., Bradford, W. Z., Starko, K., Noble, P. W., Schwartz, D. A., & King, T. E. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa030511 · Cited by 652
Research works printed but not linked: 33
- 2000, Am J Respir Crit Care Med, 646
- 2006, Proc Am Thorac Soc, 364
- 2007, Eur Respir J, 835
- 2005, Crit Rev Immunol, 429
- 2005, Am J Respir Crit Care Med, 417
- 2008, Eur J Pharmacol, 44
- 2002, Eur J Cancer, S28
- 2002, N Engl J Med, 683
- 2006, N Engl J Med, 1278
- 2005, N Engl J Med, 1412
- 2004, J Clin Invest, 1308
- 2007, Am J Respir Crit Care Med, 1243
- 2005, Am J Respir Crit Care Med, 1279
- 2004, N Engl J Med, 125
- 2008, Am J Respir Crit Care Med, 75
- 2008, Am J Respir Crit Care Med, 948
- 2006, Am J Respir Crit Care Med, 810
- 2007, Am J Respir Crit Care Med, 636
- 2008, Respiration, 350
- 2004, Leukemia, 645
- 2008, Eur Respir J, 170
- 2007, Am J Respir Cell Mol Biol, 291
- 2005, Circ Res, 784
- 2005, J Clin Invest, 2811
- 2006, Br J Clin Pharmacol, 97
- 2002, Am J Respir Crit Care Med, 277
- 2007, Am J Respir Crit Care Med, 1054
- 2005, N Engl J Med, 2229
- 2005, Am J Respir Crit Care Med, 1040
- 2006, Curr Mol Med, 409
- 2008, Arthritis Rheum, 2538
- 2008, Eur Respir J, 232
- 2004, Inflamm Res, 133
Cited by
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Self-citationMechanisms of fibrosis: therapeutic translation for fibrotic disease
Wynn, T. A., & Ramalingam, T. R. (2012) · Nature Medicine · doi:10.1038/nm.2807 · Cited by 3,541
“…inhibitor imatinib mesylate (Gleevec), which inhibits signaling of PDGF receptor and vascular endothelial growth factor receptor, did not affect survival or lung function in patients with IPF 168 , ongoing trials are investigating its potential as a treatment for nephrogenic systemic fibrosis 169 .”
King, T. E., Pardo, A., & Selman, M. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60052-4 · Cited by 2,194
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
Noble, P. W., Albera, C., Bradford, W. Z., Costabel, U., Glassberg, M. K., Kardatzke, D., King, T. E., Lancaster, L., Sahn, S. A., Szwarcberg, J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60405-4 · Cited by 2,154
Richeldi, L., Collard, H. R., & Jones, M. G. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30866-8 · Cited by 2,020
Metadata
- Authors
- Daniels, C. E., Lasky, J. A., Limper, A. H., Mieras, K., Gabor, E., & Schroeder, D. R.
- Affiliations
- Mayo Clinic (US)
- Tulane University (US)
- Venue
- American Journal of Respiratory and Critical Care Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 2010-03
- Volume
- 181
- Issue
- 6
- Pages
- 604-610
- ISSN
- 1073-449X (ISSN-L)
- 1535-4970
- OpenAlex
- W2111459732
- Cited by
- 373
- References
- 34
- Citations by year
- 2026: 8 · 2025: 10 · 2024: 11 · 2023: 7 · 2022: 15 · 2021: 10 · 2020: 17 · 2019: 12 · 2018: 25 · 2017: 27 · 2016: 29 · 2015: 39 · 2014: 19 · 2013: 43 · 2012: 42
- FWCI
- 27.88
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Respiratory and Critical Care Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
- Keywords
- idiopathic pulmonary fibrosis, imatinib, tyrosine kinase inhibitors, pulmonary fibrosis, forced vital capacity decline, mortality, diffusing capacity for carbon monoxide, arterial oxygenation, drug safety, treatment efficacy
- MeSH terms
- Imatinib Mesylate, Aged, Anemia, Benzamides, Double-Blind Method, Dyspnea, Feasibility Studies, Female, Follow-Up Studies, Gastrointestinal Diseases, Hematoma, Subdural, Humans, Leukopenia, Male, Middle Aged, Piperazines, Pyrimidines, Respiratory Function Tests, Survival Analysis, Treatment Outcome, Disease Progression, Protein Kinase Inhibitors, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Imatinib Treatment for Idiopathic Pulmonary Fibrosis: Randomized Placebo-controlled Trial Results. https://app.cochat.ai/papers/10.1164/rccm.200906-0964oc
- The paper
- Daniels, C. E., Lasky, J. A., Limper, A. H., Mieras, K., Gabor, E., & Schroeder, D. R. (2010). Imatinib Treatment for Idiopathic Pulmonary Fibrosis: Randomized Placebo-controlled Trial Results. American Journal of Respiratory and Critical Care Medicine. https://doi.org/10.1164/rccm.200906-0964oc
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.